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Behçet’s disease (BD) is a multisystem inflammatory disorder that presents as re-
current oral and genital ulcers in conjunction with other dermatological and ocular 
manifestations. The prevalence of BD is higher in Middle and East Asia than in 
Western countries. Intestinal BD is a specific subtype of BD, characterized by in-
testinal ulcers and associated gastrointestinal symptoms. Similar to inflammatory 
bowel disease, intestinal BD exhibits a fluctuating disease course with repeated 
episodes of relapse and remission that necessitate adequate maintenance therapy 
after achievement of clinical remission. Medical treatment of intestinal BD is 
largely empirical since well-controlled studies have been difficult to perform due 
to the heterogeneity and rarity of the disease. To date, 5-aminosalicylic acid, sys-
temic corticosteroids, and immunosuppressants have been used anecdotally to 
treat intestinal BD. The clinical course of intestinal BD shows considerable vari-
ability, and the exact point at which more potent agents such as immunosuppres-
sants should be used has not yet been elucidated. Given the difficulty in predicting 
which patients will experience complicated disease courses and the fact that these 
drugs are related with certain risk resulting from immunosuppression, proper iden-
tification of prognostic factors in intestinal BD may allow physicians to implement 
tailored medical therapy and individualized patient monitoring based on risk strati-
fication. In this review, the impact of baseline characteristics on the long-term 
course of intestinal BD, prognostic factors during various medical therapies, and 
outcome predictors related to surgery will be discussed.
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INTRODUCTION
Behçet’s disease (BD) is a chronic relapsing multisystemic vasculitic disorder 
characterized by recurrent oral and genital ulcers, ocular lesions, skin manifesta-
tions, arthritis, as well as vascular, neurologic, and intestinal involvement.1,2 The 
disease prevalence is relatively high in East Asia, including Korea and Japan, as 
well as in Mediterranean countries with approximately 1-10 cases per 10000 peo-
ple. In Europe and North America, however, the prevalence is considerably lower 
at a rate of only 1-2 patients per 1000000 people.3,4 While the prognosis for BD 
varies, involvement of the central nervous system and large blood vessels often re-
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tation of tailored treatment and individualized monitoring 
strategies. Although clinical data for specific outcomes of 
intestinal BD are not yet sufficient, multiple studies regard-
ing these issues have been published over the last decade. 
In this review, the impact of baseline characteristics on the 
long-term course of intestinal BD, prognostic factors for 
various medical treatments, and outcome predictors related 
to surgery will be discussed.
LONG-TERM OUTCOME PREDICTORS 
FOR INTESTINAL BEHÇET’S DISEASE
There are very scant data on clinical predictors of the long 
term evolution of intestinal BD. In one retrospective study 
carried out by Jung, et al.17 including 130 patients who were 
regularly followed for more than 5 years at a single tertiary 
academic medical center, a large proportion of patients 
(71.5%) experienced a mild clinical course, whereas the re-
maining 28.5% of patients had a severe clinical course with 
multiple relapses or chronic symptoms. Therein, initial pre-
sentation with higher disease activity [disease activity index 
for intestinal Behçet’s disease (DAIBD) ≥40] was indepen-
dently associated with a more severe clinical course [odds 
ratio (OR), 6.2; 95% confidential interval (CI), 1.1-33.5]. 
It has been reported that the cumulative rates of surgical 
intervention are 20% at 1 year, 27-33% at 5 years, and 31-
46% 10 years after diagnosis.18,19 Regarding predictors for 
requiring an operation, younger age (<40 years) at the time 
of diagnosis [hazard ratio (HR), 2.41; 95% CI, 1.28-4.54], 
higher initial disease activity (DAIBD ≥70) (HR, 5.43; 95% 
CI, 2.65-11.1) and the presence of volcano-shaped intesti-
nal ulcers (HR, 6.99; 95% CI, 2.75-17.73) (Fig. 1) were in-
dependent predictive factors.18
OUTCOME PREDICTORS DURING 
VARIOUS MEDICAL TREATMENTS
Overall outcomes during medical treatment
Remission rates 8 weeks after the initiation of medical treat-
ment have been reported to be 38-67% in cases of intestinal 
BD.20,21 Kim, et al.22 reported that patients with volcano-type 
ulcers showed a significantly lower complete remission rate 
in response to initial medical therapy than those with non-
volcano type ulcers (24% versus 68%, respectively, p<0.05). 
Despite an initial response to medical treatment, a substan-
sults in a fatal prognosis.5
Because gastrointestinal (GI) involvement can also lead 
to severe morbidity and mortality, BD is particularly desig-
nated ‘‘intestinal BD’’ if GI symptoms predominate, and 
typical ulcerative GI lesions are objectively documented.6 
The frequency of GI involvement varies depending on geo-
graphic location, ranging from 3% to 50%.7-10 Symptomatic 
or documented intestinal involvement is rare in Mediterra-
nean patients with BD, whereas it is common in East Asian 
countries including Korea and Japan. The most frequently 
affected site is the ileocecal region, and common clinical 
symptoms include abdominal pain, diarrhea, and bleeding.11 
Although the diagnosis of systemic BD is usually made ac-
cording to criteria suggested by the Behçet’s Disease Re-
search Committee of Japan12 or the International Study 
Group for Behçet’s Disease,13 adequate diagnosis of intesti-
nal BD using these criteria is limited due to various extraint-
estinal manifestations that emerge at different time points 
throughout the disease course.14 Therefore, novel diagnostic 
criteria for intestinal BD were recently proposed, which 
may be particularly useful in patients with ileocolonic ul-
cers that do not fully satisfy the diagnostic criteria for sys-
temic BD.15
Similar to inflammatory bowel disease (IBD), including 
Crohn’s disease and ulcerative colitis, intestinal BD runs a 
chronic, fluctuating, and unpredictable course characterized 
by repeated episodes of relapse and remission.16 As a result, 
the primary goals of intestinal BD management are induc-
tion and maintenance of symptom remission to minimize re-
currences, surgical procedures, and irreversible bowel dam-
age.7 However, optimal medical treatment for intestinal BD 
has not been firmly established due to the rarity of the dis-
ease, which has limited the ability to conduct well-controlled 
clinical studies. Currently, treatment of intestinal BD is large-
ly accomplished using IBD medications including 5-amino-
salicylic acid (5-ASA), corticosteroids, and immunosup-
pressants.1 
The clinical course of intestinal BD varies considerably 
from patient to patient, and the exact time point at which 
more potent agents such as immunosuppressants should be 
introduced has not yet been elucidated. Given the difficulty 
in predicting which individuals will experience complicated 
courses or inevitable surgery and the fact that these thera-
peutic agents are associated with certain risks resulting from 
immunosuppression, proper identification of prognostic fac-
tors for intestinal BD may help facilitate risk stratification at 
an earlier stage of the disease, and thus, allow for implemen-
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To date, there is limited data regarding specific serologic 
markers for intestinal BD. Based on a cohort of 106 medi-
cally treated intestinal BD patients, Choi, et al.25 found that 
the cumulative probability of a first operation was signifi-
cantly higher in patients with anti-Saccharomyces cerevisiae 
antibody (ASCA)-positive intestinal BD than in those that 
were ASCA-negative (44.8% and 17.2% at 1 year, and 53% 
and 24.3% 2 years after diagnosis, respectively, p=0.006). 
This finding implies that ASCA positivity could predict a 
more aggressive disease course in patients with intestinal 
BD. Additionally, Naganuma, et al.26 reported that the base-
line percentage of peripheral CD8+DR+lymphocytes in pe-
ripheral blood in intestinal BD patients during remission 
was significantly higher in patients with recurrence than in 
those without recurrence (10.4±2.5% versus 4.3±1.2%, re-
spectively, p=0.037), suggesting that peripheral CD8+DR+ 
lymphocytes are a potential marker for relapse. Another re-
cent study examining anti-α-enolase antibody (AAEA) 
showed that the cumulative rate of steroid use in patients 
that were positive for IgM AAEA was significantly higher 
than those that were negative (38% and 31% at 1 year, 46% 
and 43% at 3 years, and 60% and 48% at 5 years, respec-
tively, p=0.022).27 Early documentation of these serologic 
markers, if the clinical setting is available, might be useful 
for prognostic identification of intestinal BD patients.
Predictors during 5-ASA therapy 
Although there is a lack of high level evidence regarding 
the efficacy of 5-ASA, the use thereof is indicated in all 
cases of intestinal BD due to its relatively high safety pro-
file and limited alternative therapeutic options.1,7 The opti-
mal doses of mesalazine and sulfasalazine for adult patients 
are 2.25-3 g/day and 3-4 g/day, respectively. In a retrospec-
tive cohort study of 143 patients with intestinal BD who re-
ceived 5-ASA/sulfasalazine alone for maintenance of remis-
sion, Jung, et al.28 found that the cumulative relapse rates at 
1, 3, 5, and 10 years after remission were 8.1%, 22.6%, 
tial number of patients experienced relapse during the fol-
low-up period. Several studies have reported cumulative re-
currence rates of 25% at 2 years and 43-49% at 5 years 
after medically induced remission with single or combined 
drug therapies including 5-ASA/sulfasalazine, corticoste-
roids, and immunosuppressants.20,21 Regarding outcome 
predictors after medically induced remission, Chung, et al.21 
identified several predictive factors for relapse including a 
lack of complete remission after 8 weeks of medical treat-
ment (HR, 4.599; 95% CI, 2.005-10.547), the presence of 
volcano-type ulcers (HR, 3.247; 95% CI, 1.666-6.328) or 
deep ulcers (HR, 4.051; 95% CI, 1.777-9.235), and the pres-
ence of apparent GI symptoms at the time of diagnosis (HR, 
3.650; 95% CI, 1.853-7.191). Additionally, in a 2 year fol-
low-up study of 80 intestinal BD patients that had achieved 
clinical remission, Yim, et al.23 found that lack of mucosal 
healing at the time of clinical remission was an independent 
predictor of relapse (HR, 3.891; 95% CI, 1.616-9.346). This 
result was in agreement with previous IBD data that showed 
that mucosal healing was associated with sustained clinical 
remission and reduced rates of hospitalization and surgical 
resection.24
In medically treated patients, Choi, et al.20 showed that pa-
tients who achieved complete remission of intestinal lesions 
after 8 weeks of medical treatment had a lower probability 
of receiving an operation than those who had not (13% and 
36% at 2 years, and 13% and 43% at 5 years, respectively, 
p=0.028). This finding implies that mucosal healing is an 
important prognosticator for future surgery. In the same con-
text, Chung, et al.21 showed that characteristics of baseline 
endoscopic lesions could predict future surgery in medically 
treated intestinal BD patients [volcano-shaped ulcer (HR, 
3.830; 95% CI, 1.179-12.447), deep ulcers (HR, 9.723; 95% 
CI, 1.262-74.933)]. These results corroborate data reported 
by Kim, et al.22 which also showed a higher surgical rate in 
patients with volcano-type ulcers than in non-volcano type 
ulcers (52% versus 12%, respectively, p<0.05). 
Fig. 1. Volcano-type ulcers in patients with intestinal Behçet’s disease. The ileocolonoscopic findings show large, well-demarcated, deeply penetrating ul-
cers with nodular margins.
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remission were 5.8%, 43.7%, and 51.7%, respectively.30 
Younger age (<25 years) at the time of diagnosis (HR, 7.20; 
95% CI, 1.64-31.53) and a lower hemoglobin level (<11 g/
dL) (HR, 14.77; 95% CI, 2.94-74.19) at the time of remis-
sion were independent predictive factors for relapse in this 
population.30 
Predictors during biologic agent therapy
Although corticosteroids and immunosuppressants are ef-
fective treatments for intestinal BD, patients who are refrac-
tory to these conventional therapies will eventually require 
ileocecal resection. However, these surgical patients have a 
higher risk of recurrent disease than patients receiving medi-
cal therapy alone.26 Since it is known that tumor necrosis 
factor-α (TNF-α) contributes to the pathogenesis of BD,31 
agents which block TNF-α may have therapeutic potential. 
Several case series have reported that infliximab, a chimeric 
monoclonal antibody against TNF-α, is effective for induc-
ing and maintaining remission in cases of intestinal BD.32-39 
In a recent multicenter retrospective study of 28 cases of cor-
ticosteroid or immunosuppressant non-responsive intestinal 
BD,40 18 (64.3%) showed a clinical response [including 8 
patients (28.6%) with clinical remission] 4 weeks after the 
initiation of infliximab therapy. Moreover, at 30 weeks, 13 
(50.0%) showed a clinical response [including 12 patients 
(46.2%) with clinical remission]. Independent predictors of 
a sustained response to infliximab were older age (>40 
years) at the time of diagnosis (OR, 8.7; 95% CI, 1.173-
64.581), female gender (OR, 13.72; 95% CI, 1.574-119.617), 
longer disease duration (≥5 years) (OR, 9.19; 95% CI, 1.234-
68.394), concomitant immunosuppressant use (OR, 33.96; 
95% CI, 1.480-779.212), and clinical remission at 4 weeks 
after the initiation of treatment (OR, 8.93; 95% CI, 1.457-
55.556).40
OUTCOME PREDICTORS RELATED TO 
SURGICAL TREATMENT
Surgical resection is indicated for patients who are unrespon-
sive to medical treatments or those with bowel complications 
including stricture, fistula, severe bleeding, or perforation. Of 
these complications, bowel perforation is the most serious 
and necessitates emergent operative management. Moon, et 
al.41 previously conducted a study in 129 patients with symp-
tomatic intestinal BD, showing that 33 (25.6%) patients were 
diagnosed with intestinal perforation and underwent subse-
31.2%, and 46.7%, respectively. Independent factors associ-
ated with relapse were younger age (<35 years) at the time 
of diagnosis (HR, 18.17; 95% CI, 1.30-254.75), higher C-
reactive protein (CRP) level (≥1.5 mg/dL) (HR, 2.08; 95% 
CI, 1.01-4.29), and greater disease activity (DAIBD ≥60) at 
the time of 5-ASA/sulfasalazine initiation (HR, 2.30; 95% 
CI, 1.10-4.83).28 
Predictors during corticosteroid therapy
Corticosteroids are indicated for patients with disease that 
is refractory to 5-ASA, severe systemic symptoms, recur-
rent GI bleeding, or moderate to severe disease activity.1 
The initial dose of corticosteroids for these patients is 0.5-1 
mg/kg per day of prednisolone for 1-2 weeks. When clini-
cal improvement is observed, prednisolone should be ta-
pered by 5 mg each week. Greater than 10 mg of predniso-
lone per day is not advised for long periods of time.1 In a 
retrospective cohort study of 54 patients with moderate to 
severe intestinal BD that were treated with a first course of 
systemic corticosteroids (mean starting dosage, 0.58 mg/kg; 
range, 0.39-1.20 mg/kg), there were 25 (46.3%) patients 
with complete remission, 23 (42.6%) patients with partial 
remission, and 6 (11.1%) patients who showed no response 
at 1 month post-treatment.29 After 1 year, 26 (48.1%) patients 
remained in prolonged response status, 19 (35.2%) patients 
showed corticosteroid dependency, and the remaining 4 
(7.4%) patients had undergone surgery. The cumulative prob-
abilities of surgery for this cohort were 17.5% and 49.1% at 1 
and 3 years, respectively. In this cohort, prolonged response 
at 3 months was the only factor that was independently asso-
ciated with a decreased risk of surgery in the long-term (HR, 
0.176; 95% CI, 0.048-0.649).29 
Predictors during immunosuppressant therapy
Immunosuppressants are indicated when patients are corti-
costeroid-dependent or corticosteroid-resistant.1 Currently, 
thiopurines including 6-mercaptopurine and its pro-drug, 
azathioprine, are the main empiric therapeutic agents used 
for maintenance in patients with intestinal BD. The standard 
dose of azathioprine used in this population is 50-100 mg/
day.1 In a single center cohort study performed by Jung, et 
al.,30 the cumulative rates of thiopurine requirement in pa-
tients with intestinal BD at 1 year, 5 years, and 10 years after 
diagnosis were 10.5%, 22.1%, and 32.3%, respectively. 
Among 39 patients who underwent thiopurine therapy for 
maintaining medically or surgically induced remission, the 
cumulative relapse rates at 1 year, 3 years, and 5 years after 
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quent surgery during follow-up. Younger age (≤25 years) at 
the time of diagnosis (HR, 3.25; 95% CI, 1.41-7.48), a histo-
ry of prior laparotomy (HR, 5.53; 95% CI, 2.25-13.56), and 
volcano-shaped intestinal ulcers (HR, 2.84; 95% CI, 1.14-
7.08) were identified as independent risk factors for bowel 
perforation in patients with intestinal BD.41
Regarding post-operative outcomes in intestinal BD, Choi, 
et al.20 showed that the cumulative recurrence rates of intes-
tinal lesions were 28% at 1 year, 49% at 2 years, and 75% 
at 5 years. Most recurrences occurred at the anastomotic 
site or within the vicinity of the site (81%, 25/31) as deter-
mined by endoscopy.20 Among the clinical variables stud-
ied, previous surgery for perforation or fistula was the only 
significant factor associated with post-operative endoscopic 
recurrence (p=0.020).20 More recently, Jung, et al.42 showed 
that the cumulative clinical recurrence rates after surgical 
treatment in 72 patients with intestinal BD were 29.2% at 2 
years and 47.2% at 5 years. In that study, they identified 
volcano-shaped ulcers (HR, 14.34; 95% CI, 3.52-58.41), 
higher CRP level (>4.4 mg/dL) (HR, 4.13; 95% CI, 1.23-
13.88), and intestinal perforation on surgical pathology 
(HR, 4.77; 95% CI, 1.12-20.33) as independent predictors 
of recurrence.42
Cumulative reoperation rates have been reported as 13-
18% at 2 years and 22-38% five years after initial sur-
gery.19,20,42 Regarding outcome predictors for a second sur-
gery, Choi, et al.20 reported that patients who received post-
operative azathioprine had lower reoperation rates than 
those that did not (7% versus 25% at 2 years, 25% versus 
47% at 5 years, respectively, p=0.035). Beyond that, Jung, 
et al.42 found that volcano-shaped ulcers (HR, 47.98; 95% 
CI, 4.21-547.35), higher CRP levels (>4.4 mg/dL) (HR, 
46.85; 95% CI, 1.88-1170.25), and a history of postopera-
Table 1. Outcome Predictors for Intestinal Behçet’s Disease
Long-term outcome predictors for intestinal BD
    1. Predictors of a severe disease course:
        Higher disease activity (DAIBD ≥40) at the time of diagnosis17 
    2. Predictors for operation:
        Younger age (<40 yrs) at the time of diagnosis18
        Higher initial disease activity (DAIBD ≥70)18
        Volcano-type ulcers18
Outcome predictors under various medical therapies
    1. Predictors after overall medical treatment
        1) Predictors of lack of complete remission after initial  medical 
             therapy: Volcano-type ulcers*22
        2) Predictors of relapse:
             Absence of initial remission at 8 wks21
             Volcano-type ulcers21
             Apparent GI symptoms at the time of diagnosis21
             Lack of mucosal healing at the time of clinical remission23
             Higher percentage of peripheral CD8+DR+lymphocytes at the 
               time of remission*26
        3) Predictors of surgery:
             Lack of complete remission of intestinal lesions at 8 wks*20
             Volcano-type ulcers*21,22
             Deep ulcers21
             ASCA positivity*25
        4) Predictors of steroid use: AAEA positivity*27
    2. Predictors during 5-ASA therapy
        1) Predictors of relapse:
             Younger age (<35 yrs) at the time of diagnosis28
             Higher CRP level (≥1.5 mg/dL) at initiation of 5-ASA28
             Higher disease activity (DAIBD ≥60) at initiation of 5-ASA28
    3. Predictors during corticosteroid therapy
        1) Predictors of surgery: 
             Lack of prolonged response 3 months after corticosteroid 
               initiation29
    4. Predictors during immunosuppressant (thiopurine) therapy 
        1) Predictors of relapse:
             Younger age (<25 yrs) at the time of diagnosis30
             Lower hemoglobin (<11g/dL) level at the time of remission30
    5. Predictors during infliximab therapy 
        1) Predictors of sustained response: 
            Older age (≥40 yrs) at the time of diagnosis40
            Female gender40
            Longer (≥5 yrs) disease duration40
            Concomitant immunomodulator use40
            Achievement of remission at 4 wks40
Outcome predictors related to surgical treatment 
    1. Predictors of free bowel perforation: 
        Younger age (≤25 yrs) at the time of diagnosis41
        History of prior laparotomy41
        Volcano-type ulcers41
    2. Predictors of postoperative endoscopic recurrence:
        Previous surgical indication with perforation or fistula*20
Table 1. Continued
    3. Predictors of relapse after first surgery: 
        Volcano-type ulcers42
        Higher CRP level (>4.4 mg/dL)42
        Intestinal perforation on surgical pathology42
    4. Predictors of a second operation:
        Absence of postoperative azathioprine use*20
        Volcano-type ulcers42
        Higher CRP level (>4.4 mg/dL)42
        History of postoperative steroid therapy42
BD, Behçet’s disease; DAIBD, disease activity index for intestinal Behçet’s 
disease; GI, gastrointestinal; ASCA, anti-Saccharomyces cerevisiae anti-
body; AAEA, anti-α-enolase antibody; 5-ASA, 5-aminosalysilic acid; CRP, 
C-reactive protein.
*Unadjusted results. 
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CONCLUSIONS
 
In this review, several clinical variables including younger 
age, higher disease activity at the time of diagnosis, volca-
no-type ulcers, absence of mucosal healing, higher CRP 
level, history of surgery, and lack of initial response to med-
ical therapy were repeatedly shown to be poor prognostic 
factors in patients with intestinal BD (Table 1). These clini-
cal predictors may help physicians in guiding adequate pa-
tient monitoring and individually optimized treatment based 
on risk stratification. Nevertheless, application of these di-
verse predictors into daily practice seems somewhat limit-
ed, and the true predictive power of these parameters has not 
yet been evaluated in an independent population. Therefore, 
studies with the aim of developing a validated prediction 
model for clinical outcomes in intestinal BD are warranted. 
Moreover, the clinical efficacy of tailored management strat-
egies based on risk stratification such as early use of immu-
nosuppressants and intensive patient monitoring in patients 
that are at higher risk for unfavorable outcomes should also 
be confirmed. Given the growing body of research in genet-
ics and pharmacogenomics, more accurate predictions of 
clinical courses for patients with intestinal BD may be pos-
sible in the near future. 
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